Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of oltipraz in reversing the aging phenotype of human childhood progeria

A technology of progeria and oltipraz applied in the field of biomedicine

Active Publication Date: 2018-06-19
INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are no in vitro and in vivo studies on the use of small molecule compounds to effectively improve the aging phenotype of adult stem cells derived from HGPS patients
There is no report on the use of oltipraz in HGPS related studies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of oltipraz in reversing the aging phenotype of human childhood progeria
  • Use of oltipraz in reversing the aging phenotype of human childhood progeria
  • Use of oltipraz in reversing the aging phenotype of human childhood progeria

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1. Identification of HGPS-MSCs and their aging phenotypes

[0060] 1. Culture of HGPS patient-derived induced pluripotent stem cells and differentiation of MSCs

[0061] HGPS patient-derived iPSCs (HGPS-iPSCs), in which the LMNA gene is mutated (the LMNA genome sequence is GenBank: NG_008692.2; the cDNA sequence is GenBank: NM_170707.3), and the mutation type is C1824T (GGGCG is mutated to GGTGG). The site reference sequence is the CDS region in the LMNA cDNA sequence GenBank: NM_170707.3. In this example, HGPS-iPSCs were further differentiated into mesenchymal stem cells (HGPS-MSCs) in vitro. The specific method is as follows:

[0062] The HGPS-iPSCs were differentiated into embryoid bodies (EBs) for 14 days. The EBs were seeded in matrigel-coated 6-well plates and cultured for 2 weeks until fibrous cells appeared. After another passage, flow cytometry was used to sort the cell groups that were positive for CD73, CD90 and CD105, which were HGPS patient-deriv...

Embodiment 2

[0085] Example 2. Using HGPS-MSC to screen small molecular compounds for anti-aging phenotypes

[0086] When the inventors of the present invention cultivated the HGPS-MSCs prepared in Example 1, they established a screening method for small molecular compounds targeting anti-aging phenotypes, and found that Oltipraz can reverse the aging phenotypes of HGPS-MSCs. details as follows:

[0087] HGPS-MSC cells were divided into 5×10 4 Each well was spread in a six-well plate, and the second day after the cells adhered to the wall, in the experimental group, 25 μM Oltipraz (Oltipraz) medium was added to continue culturing (while setting the HGPS-MSC without Oltipraz treatment cells as a control) were continuously cultured for 21 hours, during which three cell passages were experienced, and then the HGPS-MSCs and controls treated with the oltipraz (Oltipraz) were analyzed as follows:

[0088] (1) Senescence-associated β-galactosidase staining

[0089] The specific method is carri...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of oltipraz in reversal of senescence-like phenotype of Hutchinson-Gilford progeria syndrome (HGPS). The invention provides a new use (I) or (II) of oltipraz specifically as follows: (I) application in the preparation of a product for delaying or reversing the senescence-like phenotype of HGPS; (II) application in the delay or reversal of the senescence-like phenotype of HGPS. Experiments show that oltipraz can reduce the proportion of positive beta-galactosidase staining cells in HGPS-MSCs, increase the expression quantity of nuclear membrane-associated proteins LAP2 and / or LaminB1, and improve the survival ability of HGPS-MSCs in vivo, namely, oltipraz can improve the senescence-like phenotype of HGPS-MSCs and is important to delay or reverse the senescence-like phenotype of HGPS.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to a new application of oltipraz, in particular to the application of oltipraz in reversing the aging phenotype of progeria in human children. Background technique [0002] Aging is a process in which the human body gradually becomes disordered, and is considered to be the most influential pathogenic factor for various diseases such as tumors and cardiovascular diseases. The human body has a certain self-renewal ability, and this self-renewal ability is also strictly regulated. With the aging of the body, the self-regulating balance of stem cells is destroyed, and the regeneration ability of tissues and organs decreases, which leads to aging-related diseases. Therefore, stem cell senescence is currently considered to be one of the important causes of body aging, and how to delay or reverse stem cell senescence has become a research hotspot in the field of basic and translational research on...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/497A61P43/00
CPCA61K31/497
Inventor 刘光慧曲静张维琦任若通杨济平王丽霞
Owner INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com